Prime Vitality, Inc. dba Prime Peptides

Semaglutide can help people who are obese or overweight lose a considerable amount of weight and lower their risk of heart disease, diabetes, and cancer when used in combination with diet and exercise.

Retatrutide improves glycemic control. In a study involving patients with type 2 diabetes, retatrutide reduced HbAlc levels by up to 2.02% at 24 weeks. This indicates better blood sugar control, which is crucial for managing diabetes.

Retatrutide reduces liver fat. A 48-week study showed that retatrutide significantly reduced liver fat in obese patients. Those taking 8 mg and 12 mg doses saw liver fat reductions of 23.8% and 25.9% respectively, which is beneficial for liver health.

Semaglutide . . .Pros: Reduces body weight, controls blood sugar levels, FDA-approved for weight management . . . Statistics: Clinical trials show up to 15% body weight loss

Retatrutide enhances cardiometabolic health. Participants in the trial experienced improvements in cardiometabolic measures, including reductions in waist circumference, blood pressure, and lipid levels. For examples, waist circumference decreased by up to 19.6 cm in some participants.

GLP-1 peptides also improve your overall health by controlling blood sugar and lowering the risk for heart problems, which are often an issue for people who are overweight. Let's start by talking about the most popular weight loss peptide, semaglutide. Semaglutide is a medication that can help people with weight-related health issues like type 2 diabetes, high cholesterol, and high blood pressure.

Mechanism of Action[,] GLP-1 Receptor Activation[,] Appetite Regulation[,] Slowing Gastric Emptying[,] Enhancing Insulin Secretion[,] Reducing Glucagon Production[,] Cardiovascular Benefits[,and] Energy Expenditure and Lipid Metabolism

Retatrutide is an emerging peptide developed by Lilly for treating obesity, diabetes, and fatty liver disease. It is common for diabetes medications to be used for weight management, and Retatrutide is a notable example of this trend.

Semaglutide reduces cardiovascular events. The SELECT trial showed that semaglutide reduced major adverse cardiovascular events by 20% in adults with preexisting cardiovascular disease and obesity. This included fewer heart attacks and strokes compared to those on placebo.

Retatrutide is a new medicine that helps control blood sugar and supports weight loss. . . . Safe & Effective: Trusted by health professionals worldwide

Semaglutide is a GLP-1 receptor agonist known for its significant impact on weight loss, glycemic control, and cardiovascular risk reduction. . . Safe & Effective: Trusted by health professionals worldwide

Retatrutide . . . Pros: Targets 3 pathways, most weight loss, treats fatty live . . . Fun Fact: Known as the 'triple agonist' for its multi-pathway approach. Statistics: Early trials indicate up to 25% body weight loss.

Semaglutide improves insulin resistance. A study found that semaglutide helped improve insulin sensitivity in participants, which is crucial for managing and preventing type 2 diabetes. This improvement was seen alongside significant weight loss.

Another exciting peptide is retatrutide. It was developed by Lilly for treating obesity, diabetes, and fatty liver disease . . . What sets retatrutide apart is its triple action approach. Unlike other medications like semaglutide which only targets GLP-1 receptors, retatrutide works on three types of receptors; GIP, GLP-1, and glucagon. This unique combination helps extend feelings of fullness by slowing down the rate at which the stomach empties after meals. It also helps stabilize blood sugar levels by boosting insulin release and converting excess sugar into glucose.

Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.

Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.